The Role of the Tumor Microenvironment in the Pathophysiology of Urological Cancers

Urological cancers, including prostate, bladder, and kidney cancers, represent a group of diseases where the processes of tumor development and progression are influenced by complex cellular and molecular interactions within the tumor microenvironment (TME). Stromal fibroblasts, immune system cells, blood vessel endothelial cells, and extracellular matrix (ECM) components make up the TME, which collectively affect tumor growth, invasion, and treatment resistance. Prostate cancer can continue to grow even in the absence of androgens due to changes in the stroma and signaling via the androgen receptor. While renal cell carcinoma (RCC) exhibits a highly vascularized TME influenced by hypoxia-sensitive pathways, bladder cancer is characterized by persistent inflammation, the process of epithelial–mesenchymal transition (EMT), and mechanisms that allow immune evasion. Together, these processes alter blood vessel development, metabolism, and immune surveillance, creating an immunosuppressive environment that promotes tumor survival. Developing successful nanotherapeutic and immunomodulatory strategies that target cancer cells as well as their surrounding supportive environment requires a deep understanding of the biology of the tumor microenvironment in urological cancers.